About Us

News

July 14, 2022

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2022 Financial Results
June 13, 2022

Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022
June 8, 2022

Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
June 6, 2022

Neurocrine Biosciences Honored at CARES Foundation 22nd Anniversary Gala
June 6, 2022

Neurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients with Parkinson’s Disease and Motor Fluctuations at SLEEP 2022
May 25, 2022

Neurocrine Biosciences Announces Repurchase of Convertible Notes
May 23, 2022

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022
May 12, 2022

Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease
May 4, 2022

Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance
May 3, 2022

Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference
Products

While others walk away from neuroscience because of risk and complexity, our team persists, resulting in four FDA-approved therapies.

Learn More
Leadership Team

Our mission to relieve patient suffering begins with our leadership team. They lead our effort to relentlessly pursue medicines to ease the burden of debilitating diseases and disorders.

Learn More